HARPOON THERAPEUTICS INC's ticker is HARP and the CUSIP is 41358P106. A total of 81 filers reported holding HARPOON THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 1.35 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $20,000 | -92.5% | 10,228 | -80.9% | 0.00% | – |
| Q1 2022 | $267,000 | -29.2% | 53,595 | +7.5% | 0.00% | – |
| Q4 2021 | $377,000 | -4.6% | 49,877 | 0.0% | 0.00% | – |
| Q3 2021 | $395,000 | -83.5% | 49,877 | -71.2% | 0.00% | -100.0% |
| Q2 2021 | $2,401,000 | -26.6% | 173,102 | +10.7% | 0.00% | 0.0% |
| Q1 2021 | $3,272,000 | +69.8% | 156,379 | +34.9% | 0.00% | 0.0% |
| Q4 2020 | $1,927,000 | +4.0% | 115,963 | +6.4% | 0.00% | 0.0% |
| Q3 2020 | $1,853,000 | +56.6% | 109,016 | +53.0% | 0.00% | 0.0% |
| Q2 2020 | $1,183,000 | +123.2% | 71,262 | +55.8% | 0.00% | – |
| Q1 2020 | $530,000 | -20.7% | 45,740 | +1.3% | 0.00% | – |
| Q4 2019 | $668,000 | +9.3% | 45,159 | +1.0% | 0.00% | – |
| Q3 2019 | $611,000 | +25.5% | 44,723 | +19.6% | 0.00% | – |
| Q2 2019 | $487,000 | +70.3% | 37,399 | +24.0% | 0.00% | – |
| Q1 2019 | $286,000 | – | 30,167 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 3,156,699 | $15,689,000 | 7.73% |
| MPM ASSET MANAGEMENT LLC | 3,131,388 | $15,563,000 | 5.32% |
| MPM BioImpact LLC | 3,196,707 | $15,888,000 | 4.26% |
| ACUTA CAPITAL PARTNERS, LLC | 497,500 | $2,473,000 | 1.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 151,445 | $2,771,000 | 0.62% |
| Orbimed Advisors | 3,039,508 | $15,106,000 | 0.24% |
| Artal Group S.A. | 1,000,000 | $4,970,000 | 0.21% |
| Cormorant Asset Management, LP | 540,600 | $2,687,000 | 0.21% |
| DAFNA Capital Management LLC | 105,163 | $523,000 | 0.14% |
| Ikarian Capital, LLC | 117,009 | $582,000 | 0.08% |